Skip to main content

The bladder, situated in the pelvic region, specifically is a muscular, balloon-shaped, and hollow organ. As urine forms in the kidneys, it is stored in the bladder prior to it leaving the body through the urethra. Bladder cancer in the tissues of the urinary bladder typically refers to malignant growth/tumors.

The general form of bladder cancer begins in the inner lining of the bladder cells (transitional cell carcinoma). The other forms include squamous cell carcinoma, in which the cancer is small, cancer begins with flat cells lining inside the bladder, and adenocarcinoma in the cells that releases mucus.

Symptoms of Bladder Cancer

Urine Blood (Hematuria): Urine Blood (Hematuria) is the most common symptom and typically the initial sign of a cancer alarm. It is usually painless and, depending on the level of blood in the urine, the urine may appear light pink, brown or red (rarely). Blood is often hard to see, and urine may seem clear, but urinalysis may find small levels of blood (urine test). After the initial sighting, the blood can also vanish for weeks.

Changes in Urinary Pattern: Regular (typically more than usual) urination, pain when urinating, burning sensation, sudden urges to urinate even though the bladder is not full.

These are the initial symptoms (early stage) of bladder cancer and can correlate with signs/symptoms of other conditions, such as Bladder Stones, Urinary Tract Infection, Kidney Stones, or Male Prostate Enlargement. In all cases, however, one must visit the health specialist for a check-up.

Advance Stages Symptoms

  • Pelvic Pain
  • Being Unable to Urinate
  • Swelling in the Feet
  • Bone Pain
  • Unintentional Weight Loss
Risk Factors for Bladder Cancer

There are various variables that increase the risk of an individual developing bladder cancer.
  • Smoking
  • Gender
  • Genetic and Family History
  • Chronic Bladder Infection
  • Metal Toxins in Water
  • Chemical Exposure
  • Chemotherapy and Radiotherapy Secondary Disease
Bladder Cancer Diagnosis
By performing several tests and techniques, signs of bladder cancer can be investigated in the urine and bladder. Such assessments for diagnosis include:
  • Urinalysis
  • Cytology of Urine
  • Cystoscopy
  • Biopsy
  • Imaging Scans (CT Scanning, The MRI, Ultrasonics, Scan of Bone, X-ray procedure) 

The US FDA has approved a new type of medication for certain individuals with bladder cancer. Padcev injection (enfortumab vedotin-ejfv) can treat individuals with advanced urothelial carcinoma, which is a most common type of bladder cancer, if it gets worse after standard chemotherapy and immunotherapy treatments.

Padcev typically is a combination of two different types of medicines, known as an antibody-drug conjugate (ADC). The antibody part specifically acts like a homing signal, bringing the chemotherapy drug, monomethyl auristatin E, directly to the cells of bladder cancer with a protein named Nectin-4 on them and destroying them.

How does Padcev work: Padcev injection mainly contains enfortumab vedotin. Enfortumab vedotin has a couple of parts. One part typically belongs to a group of medicines named monoclonal antibodies (mAbs). The other belongs to a group of medicines named antimitotics. This therapy destroys the malignant cell once the antibody finds it.

Dosage Forms: This medicinal product generally comes in single-use vials containing 20 mg or 30 mg of enfortumab vedotin for injection.

Usual Dose and Administration: The dose of padcev 20 mg injection or 30 mg injection depends on the body weight. The usual starting dose is 1.25 mg for each kg of the body weight up to 100 kg. Your health specialist may need to pause, halt or reduce your Padcev dose. This can happen in case you have certain adverse reactions or in case your disease gets worse.
Dosage will be administered to you by a health specialist in a healthcare setting. It will be administered to you by intravenous (IV) infusion into the vein over 30 minutes. The medication will be given over a period of 28 days. It is known as a cycle. Patients will receive this medication once weekly for three weeks in every cycle. Then you will consider a week off prior to initiating the next cycle. A health specialist will tell you about the total number of treatment cycles you need. You may have blood tests while on treatment with this medicinal product.

Overdose: It is absolutely unlikely that you will receive excess padcev 30 mg injection or 20 mg injection as you will be precisely assessed by a health specialist during the infusion. In case you think you have taken excess dosage contact a health specialist, hospital emergency room, or any medical assistance immediately, even in case there are no signs/symptoms.

Missed Dose: In case you miss an appointment to receive your dose, you must make every effort in order to receive the missed dose as promptly as possible. Doses should be administered at least one week apart.

Side Effects: The most commonly reported padcev side effects were peripheral neuropathy (a kind of nerve damage), fatigue, nausea, taste changes, diarrhea, rash, decreased appetite, dry skin, dry eye, itching, high blood sugar levels and hair loss. Patients of reproductive potential should consider birth control while on Padcev. Use of this medicine should be avoided during pregnancy or breastfeeding.

Storage: Padcev is usually stored by the health specialist at the hospital or clinic. Store this medicinal product at 2°C to 8°C. Neither freeze not shake. Do not store any left or unused portion of the solution for reuse. Any unused medication or waste material needs to be disposed of in accordance with local requirements.

If you want to buy and more information about Padcev: Talk to your health specialist. The Padcev injection price in India is authentically reasonable. In case you want to buy or know more information about Padcev, Click on Enfortumab vedotin.

Note: On behalf of the point, many treatment options such as Surgery, Chemotherapy, Immunotherapy, Radiation Therapy are available for bladder cancer in India, and certain other variables such as patient health and preferences are available.
Nitin Goswami

Nitin Goswami joined us as an Editor in 2020. He covers all the updates in the field of Pharmaceutical, Business Healthcare, Health News, Medical News, and Pharma News.

Leave a Reply

Close Menu